more

Evelo Biosciences (EVLO)

(Delayed Data from OTC)

$0.04 USD

0.00 (-10.28%)

Updated Apr 26, 2024 10:05 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study

by Zacks Equity Research Published on October 18,2023

Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.

Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More

by Ekta Bagri Published on October 18,2023

Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.

What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock

by Zacks Equity Research Published on May 17,2023

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EVLONegative Net Change

Forget Bargain Hunting, Buy 4 Stocks With Rising P/E

by Sanghamitra Saha Published on March 16,2023

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include James River Group (JRVR), MakeMyTrip Limited (MMYT), Evelo Biosciences (EVLO) and The Kroger Co. (KR).

earnings

After Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)

by Zacks Equity Research Published on March 01,2023

Evelo Biosciences, Inc. (EVLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

EVLONegative Net Change

Down -39.46% in 4 Weeks, Here's Why Evelo Biosciences, Inc. (EVLO) Looks Ripe for a Turnaround

by Zacks Equity Research Published on February 13,2023

The heavy selling pressure might have exhausted for Evelo Biosciences, Inc. (EVLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

EVLONegative Net Change

Why Evelo Biosciences (EVLO) Might Surprise This Earnings Season

by Zacks Equity Research Published on March 02,2022

Evelo Biosciences (EVLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

EVLONegative Net Change

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Kinjel Shah Published on February 24,2022

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

biotechs

Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on February 21,2022

On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.

medical

BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on February 17,2022

On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.

Evelo Biosciences, Inc. (EVLO) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research Published on February 11,2022

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EVLONegative Net Change

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on February 09,2022

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.

medical

Wall Street Analysts Believe Evelo Biosciences, Inc. (EVLO) Could Rally 164%: Here's is How to Trade

by Zacks Equity Research Published on October 13,2021

The consensus price target hints at a 164.5% upside potential for Evelo Biosciences, Inc. (EVLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

EVLONegative Net Change

Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada

by Zacks Equity Research Published on October 08,2021

Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.

biotechs

Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study

by Zacks Equity Research Published on September 28,2021

Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.

biotechs

Implied Volatility Surging for Evelo Biosciences (EVLO) Stock Options

by Zacks Equity Research Published on September 08,2021

Investors need to pay close attention to Evelo Biosciences (EVLO) stock based on the movements in the options market lately.

EVLONegative Net Change

medical

Are Options Traders Betting on a Big Move in Evelo (EVLO) Stock?

by Zacks Equity Research Published on August 06,2021

Investors need to pay close attention to Evelo (EVLO) stock based on the movements in the options market lately.

EVLONegative Net Change

medical

Anavex (AVXL) to Report Q3 Earning: What's in the Cards?

by Zacks Equity Research Published on July 27,2021

On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.

biotechs